EG24074A - Formulation - Google Patents

Formulation

Info

Publication number
EG24074A
EG24074A EG20010017A EG20010017A EG24074A EG 24074 A EG24074 A EG 24074A EG 20010017 A EG20010017 A EG 20010017A EG 20010017 A EG20010017 A EG 20010017A EG 24074 A EG24074 A EG 24074A
Authority
EG
Egypt
Prior art keywords
formulation
Prior art date
Application number
EG20010017A
Other languages
English (en)
Inventor
John R Evans
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24074(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of EG24074A publication Critical patent/EG24074A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
EG20010017A 2000-01-10 2001-01-08 Formulation EG24074A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation

Publications (1)

Publication Number Publication Date
EG24074A true EG24074A (en) 2008-05-11

Family

ID=26243352

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010017A EG24074A (en) 2000-01-10 2001-01-08 Formulation

Country Status (41)

Country Link
US (5) US20030125387A1 (fr)
EP (4) EP1250138B2 (fr)
JP (3) JP3713237B2 (fr)
KR (1) KR100802366B1 (fr)
CN (1) CN1222292C (fr)
AR (1) AR027510A1 (fr)
AT (1) ATE306928T1 (fr)
AU (1) AU762080B2 (fr)
BE (1) BE1013477A3 (fr)
BG (1) BG65776B1 (fr)
BR (1) BR0107445B1 (fr)
CA (1) CA2351004C (fr)
CH (1) CH696260A5 (fr)
CO (1) CO5280206A1 (fr)
CY (1) CY1116520T1 (fr)
CZ (1) CZ304689B6 (fr)
DE (2) DE60114145T3 (fr)
DK (2) DK2266573T3 (fr)
EE (1) EE05421B1 (fr)
EG (1) EG24074A (fr)
ES (3) ES2543384T3 (fr)
FR (1) FR2803516B1 (fr)
GB (3) GB0000313D0 (fr)
HK (3) HK1049286B (fr)
HU (1) HU230162B1 (fr)
IL (2) IL150230A0 (fr)
IS (1) IS2932B (fr)
IT (2) ITTO20010005A1 (fr)
MX (1) MXPA02006698A (fr)
MY (1) MY118583A (fr)
NL (1) NL1017075C2 (fr)
NO (2) NO336286B1 (fr)
PL (1) PL202525B1 (fr)
PT (2) PT2266573E (fr)
RU (1) RU2263507C9 (fr)
SI (2) SI2266573T1 (fr)
SK (1) SK287221B6 (fr)
TW (1) TWI259086B (fr)
UA (1) UA75879C2 (fr)
WO (1) WO2001051056A1 (fr)
ZA (1) ZA200204165B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
WO2003100008A2 (fr) 2002-05-24 2003-12-04 Schering Corporation Anticorps anti-igfr humain neutralisant
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1623713A1 (fr) * 2004-07-09 2006-02-08 Proskelia SAS Combinaisons d'antisetrogène et d'inhibteurs de l'aromatase
CA2604393A1 (fr) * 2005-04-15 2006-10-26 Schering Corporation Methodes et compositions pour le traitement ou la prevention du cancer
US20090227552A1 (en) * 2005-09-26 2009-09-10 Kellie Ann Hooley Fulvestrant formulations
US9180088B2 (en) 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2800673A1 (fr) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Modulateur du recepteur oestrogenique et utilisation de ces derniers
WO2011159769A2 (fr) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Modulateurs de récepteur d'œstrogène d'indane et utilisations de ceux-ci
BR112013006331B1 (pt) 2010-09-16 2021-09-21 Shimoda Biotech (Pty) Ltd Formulação compreendendo fulvestranto e ciclodextrina e seu uso
EP2711010B1 (fr) 2011-05-20 2018-10-31 Capital, Business Y Gestión De Finanzas, S.L Composition pharmaceutique
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
MX2014007198A (es) 2011-12-16 2014-10-13 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos.
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
EP2836199A1 (fr) * 2012-04-09 2015-02-18 Scidose LLC Formulations de fulvestrant
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2013386732B2 (en) 2013-04-18 2018-10-18 Xi'an Libang Pharmaceutical Technology Co., Ltd. Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203132A1 (fr) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Composés de benzopyran substitués, leurs compositions et utilisations
WO2014203129A1 (fr) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinaisons de composés benzopyrane, leurs compositions et utilisations
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (fr) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Compositions de fulvestrant
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
MA39741A (fr) 2014-03-13 2017-01-18 Hoffmann La Roche Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
EP3145489A1 (fr) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Formulations d'hormones substitutives combinées naturelles et traitement hormonal substitutif
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
CN112457310A (zh) 2014-12-18 2021-03-09 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
HUE055321T2 (hu) 2015-10-01 2021-11-29 Olema Pharmaceuticals Inc Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok
CA3001526A1 (fr) 2015-10-13 2017-04-20 Themis Medicare Limited Compositions de fulvestrant
US10118910B2 (en) 2015-12-09 2018-11-06 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
WO2017175810A1 (fr) * 2016-04-06 2017-10-12 富士フイルム株式会社 Composition médicinale
WO2017174757A1 (fr) 2016-04-08 2017-10-12 F. Hoffmann-La Roche Ag Modulateurs des récepteurs d'œstrogènes tétrahydroisoquinoléine et leurs utilisations
MX2018013414A (es) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos para su uso.
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
EP3466430B1 (fr) * 2016-05-31 2020-04-29 FUJIFILM Corporation Préparation pharmaceutique
EP3472159A1 (fr) 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG Modulateurs des récepteurs des oestrogènes tétrahydro-pyrido[3,4-b]indoles et utilisations associées
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
WO2017216279A1 (fr) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Modulateurs des récepteurs des œstrogènes hétéroaryles et leurs utilisations
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
IL274433B1 (en) * 2017-11-08 2024-03-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of using them
JP2021503478A (ja) 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
WO2019151353A1 (fr) * 2018-01-31 2019-08-08 富士フイルム株式会社 Méthode de production de préparation pour injection
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
CA3101421A1 (fr) 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Promedicaments de fulvestrant
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
CA3118330A1 (fr) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
JP2022532918A (ja) 2019-05-20 2022-07-20 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
CN113260353A (zh) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 氟维司群药物组合物、其制备方法及应用
WO2021123996A1 (fr) 2019-12-20 2021-06-24 Novartis Ag Utilisations d'anticorps anti-tgf-bêtas et inhibiteurs de point de contrôle pour le traitement des maladies prolifératives
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021260528A1 (fr) 2020-06-23 2021-12-30 Novartis Ag Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
EP4251648A2 (fr) 2020-11-24 2023-10-04 Novartis AG Anticorps anti-cd48, conjugués anticorps-médicament et leurs utilisations
WO2022169780A1 (fr) 2021-02-02 2022-08-11 Les Laboratoires Servier Composés bcl-xl protac sélectifs et procédés d'utilisation
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR20230094172A (ko) * 2021-12-20 2023-06-27 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
WO2023225336A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
WO2023225320A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (fr) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
NL7711916A (nl) * 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (fr) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Composés antigestagéniques et anti-oestrogéniques pour le traitement des tumeurs dépendant des hormones
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (fr) 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5952338A (en) 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
WO1999027906A1 (fr) 1997-12-03 1999-06-10 Merck & Co., Inc. Formulations injectables a action prolongee renfermant de l'huile de ricin hydrogenee
ES2524141T3 (es) 1999-04-01 2014-12-04 Talon Therapeutics, Inc. Composiciones para tratar el cáncer
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
RU2004102393A (ru) 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
PL202525B1 (pl) 2009-07-31
HK1052884B (zh) 2006-07-14
ES2248272T3 (es) 2006-03-16
BR0107445A (pt) 2002-09-17
GB2359254A (en) 2001-08-22
CZ304689B6 (cs) 2014-09-03
SI1250138T1 (sl) 2006-02-28
US20100152149A1 (en) 2010-06-17
HUP0204137A2 (hu) 2003-04-28
CH696260A5 (de) 2007-03-15
EP1250138B1 (fr) 2005-10-19
NO337329B1 (no) 2016-03-14
EP1669073A2 (fr) 2006-06-14
JP2004107353A (ja) 2004-04-08
NL1017075A1 (nl) 2001-07-11
GB2359254B (en) 2002-06-19
PT102548A (pt) 2001-07-31
NO336286B1 (no) 2015-07-13
HUP0204137A3 (en) 2005-03-29
US7456160B2 (en) 2008-11-25
NO20023227L (no) 2002-07-03
HK1049286B (zh) 2006-04-07
BG65776B1 (bg) 2009-11-30
DE10100779A1 (de) 2001-07-26
SK287221B6 (sk) 2010-03-08
GB0000313D0 (en) 2000-03-01
PT2266573E (pt) 2015-07-28
RU2263507C9 (ru) 2020-03-18
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
JP2011190275A (ja) 2011-09-29
EE200200387A (et) 2003-10-15
IS6454A (is) 2002-07-03
EP2266573B1 (fr) 2015-06-17
HU230162B1 (hu) 2015-09-28
ITTO20010008A1 (it) 2002-07-10
EP2286818B1 (fr) 2020-03-18
MY118583A (en) 2004-12-31
ES2186517B2 (es) 2004-03-16
US8466139B2 (en) 2013-06-18
NO20150741L (no) 2002-07-03
DK1250138T4 (en) 2015-07-27
UA75879C2 (en) 2006-06-15
BR0107445B1 (pt) 2012-10-30
BG106833A (en) 2003-03-31
AR027510A1 (es) 2003-04-02
AU762080B2 (en) 2003-06-19
ES2186517A1 (es) 2003-05-01
DE60114145D1 (de) 2006-03-02
AU2386301A (en) 2001-07-24
RU2263507C2 (ru) 2005-11-10
KR100802366B1 (ko) 2008-02-13
CZ20022384A3 (cs) 2002-09-11
CN1394141A (zh) 2003-01-29
ATE306928T1 (de) 2005-11-15
DK2266573T3 (en) 2015-07-20
CY1116520T1 (el) 2017-03-15
DE60114145T2 (de) 2006-07-13
BE1013477A3 (fr) 2002-02-05
US20010020016A1 (en) 2001-09-06
EP1669073A3 (fr) 2008-03-19
RU2002121507A (ru) 2004-03-20
SK9842002A3 (en) 2003-05-02
EE05421B1 (et) 2011-06-15
US20120329766A1 (en) 2012-12-27
MXPA02006698A (es) 2002-09-30
WO2001051056A1 (fr) 2001-07-19
HK1150021A1 (en) 2011-10-28
EP2286818A1 (fr) 2011-02-23
CN1222292C (zh) 2005-10-12
JP2003519659A (ja) 2003-06-24
IL150230A0 (en) 2002-12-01
ZA200204165B (en) 2003-10-29
CA2351004A1 (fr) 2001-07-10
ITTO20010005A1 (it) 2001-07-11
KR20020073499A (ko) 2002-09-26
IS2932B (is) 2015-12-15
EP2266573A1 (fr) 2010-12-29
CA2351004C (fr) 2003-02-18
SI1250138T2 (sl) 2015-09-30
NL1017075C2 (nl) 2001-09-25
ES2543384T3 (es) 2015-08-18
EP1250138B2 (fr) 2015-07-08
HK1049286A1 (en) 2003-05-09
DE60114145T3 (de) 2015-09-17
PL356030A1 (en) 2004-06-14
HK1052884A1 (en) 2003-10-03
GB0008837D0 (en) 2000-05-31
FR2803516A1 (fr) 2001-07-13
US8329680B2 (en) 2012-12-11
ES2248272T5 (es) 2015-08-19
SI2266573T1 (sl) 2015-08-31
US20030125387A1 (en) 2003-07-03
TWI259086B (en) 2006-08-01
US20050043285A1 (en) 2005-02-24
CO5280206A1 (es) 2003-05-30
US6774122B2 (en) 2004-08-10
NO20023227D0 (no) 2002-07-03
GB0100407D0 (en) 2001-02-21
JP3713237B2 (ja) 2005-11-09
EP1250138A1 (fr) 2002-10-23
DK1250138T3 (da) 2006-01-23
IL150230A (en) 2006-10-31
FR2803516B1 (fr) 2003-03-28

Similar Documents

Publication Publication Date Title
GB2359254B (en) Formulation
GB0000891D0 (en) Formulation
EG24226A (en) Formulation
AU8420301A (en) Use
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
IL154258A0 (en) Fungicidal formulation
GB0125492D0 (en) Formulation
GB9927614D0 (en) Sterliant formulation
GB0005070D0 (en) Use
HK1054508A1 (zh) 新型製劑
GB2375048B (en) Formulation
GB2396812B (en) Formulation
GB0116619D0 (en) Formulation
GB0001144D0 (en) Glysophosate formulation
GB0023069D0 (en) Formulation
GB0004124D0 (en) Formulation
GB0010846D0 (en) Formulation
GB0007112D0 (en) Formulation
GB0112497D0 (en) Formulation
GB9902236D0 (en) Formulation
GB0022027D0 (en) Disfectant formulations
GB9917952D0 (en) Formulation
GB9923538D0 (en) Formulation
GB9915584D0 (en) Formulation